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Abstract
Background Sarcopenia, the unintentional loss of skeletal muscle mass, is associated with poor outcomes in adult patient
populations. In adults, sarcopenia is often ascertained by cross-sectional imaging of the psoas muscle area (PMA). Although
children with chronic medical illnesses may be at increased risk for muscle loss because of nutritional deﬁciencies, physical
deconditioning, endocrine anomalies, and systemic inﬂammation, consistent quantitative deﬁnitions for sarcopenia in children
are lacking. We aimed to generate paediatric reference values for PMA at two intervertebral lumbar levels, L3–4 and L4–5.
Methods In this cross-sectional study, we analysed abdominal computed tomography scans of consecutive children presenting to the emergency department. Participants were children 1–16 years who required abdominal cross-sectional imaging after
paediatric trauma between January 1, 2005 and December 31, 2015 in a large Canadian quaternary care centre. Children with
a documented chronic medical illness or an acute spinal trauma at presentation were excluded. Total PMA (tPMA) at levels L3–
4 and L4–5 were measured in square millimetres (mm2) as the sum of left and right PMA. Age-speciﬁc and sex-speciﬁc tPMA
percentile curves were modelled using quantile regression.
Results Computed tomography images from 779 children were included. Values of tPMA at L4–5 were signiﬁcantly larger
than at L3–4 at all ages, but their correlation was high for both girls (r = 0.95) and boys (r = 0.98). Amongst girls, tPMA
50th percentile values ranged from 365 to 2336 mm2 at L3–4 and from 447 to 2704 mm2 for L4–5. Amongst boys, 50th percentile values for tPMA ranged between 394 and 3050 mm2 at L3–4 and from 498 to 3513 mm2 at L4–5. Intraclass correlation
coefﬁcients were excellent at L3–4 (0.97, 95% CI 0.94 to 0.981) and L4–5 (0.99, 95% CI 0.986 to 0.995). Weight and tPMA were
correlated, stratiﬁed by sex for boys (L3–4 r = 0.90; L4–5 r = 0.90) and for girls (L3–4 r = 0.87; L4–5 r = 0.87). An online application was subsequently developed to easily calculate age-speciﬁc and sex-speciﬁc z-scores and percentiles.
Conclusions We provide novel paediatric age-speciﬁc and sex-speciﬁc growth curves for tPMA at intervertebral L3–4 and L4–
5 levels for children between the ages of 1-16 years. Together with an online tool (https://ahrc-apps.shinyapps.io/sarcopenia/
), these tPMA curves should serve as a reference enabling earlier identiﬁcation and targeted intervention of sarcopenia in
children with chronic medical conditions.
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Introduction
Sarcopenia refers to the loss of skeletal muscle mass and
strength, typically accompanying the normal aging process
as well as in chronic conditions.1,2 Sarcopenia is a major
cause of physical disability, poor quality of life, loss of independence, and death. Multiple modalities exist to evaluate
muscle mass and nutritional status in clinical practice.3
While anthropometrics (such as weight, body mass index,
mid-arm circumference, and triceps skinfold thickness) and
biochemical markers are readily clinically obtainable at the
bedside,4,5 their values may be imprecise or confounded
by disease-related complications such as concurrent ascites,
peripheral oedema and organomegaly seen in patients with
end-stage organ failure, malignancy, chronic inﬂammatory
disease conditions, or post-surgery.6–8 Specialized
investigations exist to ascertain sarcopenia, including
bioelectrical impedance and air-displacement plethysmography.9 However, these are not routinely obtained clinical
tests and require dedicated training and equipment
thereby limiting the widest utilization. Measurement of
psoas muscle area (PMA) from single slice cross-sectional
abdominal computed tomography (CT) images represents
an easily accessible and quick method to assess the presence of sarcopenia.10,11 Amongst adults, multiple deﬁnitions
of sarcopenia using PMA have been utilized, including
distinct sex-speciﬁc cut-off values in healthy and diseased
populations,12–14 as well as at different landmarks such as
discrete lumbar (L3 and L4)disc levels, intervertebral lumbar
(L3–4 and L4–5) disc levels, or the level of the
umbilicus.11,15–18
Sarcopenia is not a problem exclusive to the adults.
Children with chronic medical illnesses experience nutritional
deﬁciencies, physical deconditioning, and systemic
inﬂammation that are potentially contributory to the unintentional muscle loss demonstrated in paediatric leukaemia,
inﬂammatory bowel disease, type 2 diabetes, end-stage liver
disease, or intestinal failure.6,8,19–23 Sarcopenia has been
evaluated in the paediatric population using dual energy Xabsorptiometry24,25 and abdominal CT imaging of the PMA
at the L4 level.26 PMA reference values at various lumbar
levels have been reported in the adult literature in acknowledgement that values may be impacted by refractory ascites
and associated prominent lordosis, sacralization of the fourth
lumbar vertebra, and lumbarization of the ﬁrst sacral vertebra.27 However, reference values for adults cannot be extrapolated to growing children. Our goal was to generate sexspeciﬁc and age-speciﬁc PMA growth charts for intervertebral
lumbar (L3–4 and L4–5) disc levels by reviewing clinically obtained cross-sectional abdominal CT images for PMA values in
a cohort of otherwise healthy children presenting after acute
trauma to the emergency room of an academic health sciences centre.
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Methods
Study population
We performed a cross-sectional single-centre study at the
Hospital for Sick Children (SickKids) in Toronto, Canada. Patients were ascertained using the SickKids trauma database,
a prospectively compiled database that houses clinical, biochemical, and radiological data from children presenting to
the SickKids emergency room (ER). All children below 18
years of age presenting to the SickKids ER following acute
trauma and requiring cross-sectional abdominal CT imaging
between January 2005 and December 2015 were eligible for
inclusion. Children were excluded if their abdominal CT studies did not adequately scan the lumbar spine (L3–L5) region,
or they had one or more of the following documented medical conditions: cerebral palsy, cardiac disease, malignancies,
autoimmune diseases, diabetes mellitus, autistic spectrum
disorders, thoracolumbar spinal trauma affecting paraspinal
musculature, and chronic inﬂammatory disorders. The study
was approved by the SickKids Research Ethics Board.

Data collection
All medical charts were reviewed for relevant clinical information, including sex, age at CT (years), weight (kilogrammes),
height (metres), and other anthropometric data available.
Sex-speciﬁc and age-speciﬁc anthropometric z-scores were
calculated from the Center for Disease Control and Prevention (CDC) reference charts.28

Measurement of muscle mass
Abdominal CT images were retrieved from the SickKids Picture Archiving and Communication System (PACS). From axial
CT images, L3–4 and L4–5 levels were identiﬁed following
cross-referencing on sagittal plane reconstructions. Landmark
lumbar (L3 and L4) vertebrae were identiﬁed in the sagittal
plane by counting down from the thoracic (T12) vertebra,
which was assumed to be the most caudal rib-bearing vertebra. In cases where the exact level was unclear, we identiﬁed
the cervical C2 level (in available cases where CT of neck,
chest, and abdomen was performed) and counted vertebral
bodies downwards (Figure 1). Alternatively, a chest X-ray
was reviewed to conﬁrm 12 pairs of ribs were present, with
the most caudal pair assumed to be T12. On the corresponding axial cross-sectional images, we delineated bilateral PMA
using a dedicated free-hand region-of-interest measurement
tool available on picture archiving and communication system
at each of the intervertebral lumbar L3–4 and L4–5 levels,
assessed in square millimetres (mm2) (Figure 1). The total
PMA (tPMA) was expressed as the sum of the right and left
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 405–414
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Figure 1 Axial and sagittal images. Lumbar levels were determined on (A) sagittal computed tomography images, enabling identiﬁcation of the L3–4
and L4–5 intervertebral levels (yellow lines). (B) The axial images corresponding to these levels were then examined to determine the psoas muscle
area (red lines).

PMA in square millimetres (mm2) for each level. All PMA
measurements were performed by one paediatric radiologist
(HP). A random age-stratiﬁed subset of CT images was measured bilaterally at both L3–4 and L4–5 levels by a second
paediatric radiologist (GC) to ensure adequate interrater reliability. Both radiologists were blinded to clinical data.

Data analysis
Continuous variables were summarized using mean and standard deviation (SD). Categorical variables were summarized
using frequencies and percentages. We used quantile regression with splines to model weight curves, which we compared
with the CDC growth charts.28 A χ 2 goodness of ﬁt test was
used to obtain the model with the best ﬁt. We then used
quantile regression with smoothed fractional polynomials to
model the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentile curves for tPMA across patient ages between 1 and 16
years for both L4–5 and L3–4 levels after stratiﬁcation by
sex. Akaike’s information criterion was used for model selection. We estimated the correlation between weight with
tPMA (as measured at L3–4 and L4–5) stratiﬁed by sex using
Pearson’s correlation coefﬁcients and interrater reliability for
tPMA using intraclass correlation coefﬁcients and Bland–
Altman plots. Wilcoxon’s paired signed-rank test, overall
and stratiﬁed by sex, was used to compare tPMA between
lumbar levels. We estimated the correlation between lumbar
levels using both Spearman’s and Pearson’s correlation coefﬁcients and interrater reliability for tPMA using intraclass correlation coefﬁcients and Bland–Altman plots. To allow a

parametrization of the asymmetrical distribution of tPMA
and derive z-scores for an online tool, we determined standard deviations for half-normal distributions above and below the median based on the median and 10th and 90th
percentiles. Median, 10th, and 90th percentile for the online
tool will therefore be identical to those published in this report. For remaining percentiles, there will be small differences between the online tool and published curves. The
online tool is available as a Shiny web application built using
R. The application allows users to input patient age (or date
of birth and date of imaging), sex, lumbar level (L3–4 or L4–
5), and tPMA (square millimetres, mm2). The age input is
rounded to the nearest month and z-scores are computed
parametrically as described above. All analyses were carried
out in R, version 3.5.0.29

Results
Review of the SickKids trauma database identiﬁed a total of
882 children requiring abdominal CT imaging at time of ER
presentation between January 2005 and December 2015.
Reasons for exclusion were established chronic medical
condition (n = 33), acute lumbar spinal trauma (n = 5), and
CT imaging not capturing the targeted L3 to L5 vertebral
regions (n = 10). In addition, because of very small numbers
of children <1 year (n = 10) and ≥16 years (n = 45), these patients were excluded as well. The ﬁnal study cohort was comprised of 779 (36% female participants) children (Figure S1).
The mean patient age was 9.5 years (SD 4.4). The age
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 405–414
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distributions for both sexes were similar (Figure S2). For male
subjects, median (IQR) age was 9.91 (6.26–13.6) years. For female subjects, median (IQR) age was 9.86 (6.17–13.28) years.
Weight was normally distributed with a mean z-score of
0.4 (SD 1.1) in the overall study cohort, 0.3 (SD 1.1) in girls,
and 0.4 (SD 1.1) in boys. Figure 2 displays the weight curves
stratiﬁed by sex from 5th to 95th percentile for the study cohort in comparison with CDC growth charts. Children at the
50th percentile of our population were heavier than those
at the 50th percentile of CDC growth charts, by an average
of 3.3 kg in girls and 3.6 kg in boys (P < 0.0001). Height values
were available in only 26 (3%) of our study cohort of 779 participants and therefore were not part of subsequent analyses.

Sex-speciﬁc tPMA curves
Growth charts for tPMA with 5th, 25th, 50th, 75th, and 95th
percentile curves for boys and for girls at both lumbar levels
are presented in Figure 3 (L3–4) and Figure 4 (L4–5). At both
L3–4 and L4–5 levels, tPMA values increased with patient age.
Until the age of 7 years, tPMA values at both L3–4 and L4–5
levels were similar between sexes. From 8 years upwards,
tPMA values were larger on average in boys than girls (P <
0.05). Values of tPMA at these percentiles in 6 months increments for patient ages 1 to 16 years are available. Values for
tPMA at L4–5 were larger than those measured at L3–4
[mean difference 282 (95%CI 266 to 298) mm2, P < 0.05].
This difference was seen in both girls [mean difference 255
(95%CI 231to 280) mm2, P < 0.01] and boys [mean difference
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298 (95% CI 278 to 318) mm2, P < 0.01]. The correlation between tPMA values at L3–4 and at L4–5 was high for girls (r =
0.95, P < 0.001) and boys (r = 0.98, P < 0.01). Psoas muscle
conﬁguration was subjectively rounder at L4–5 than L3–4.
Figure 5 shows the high correlation between weight and
tPMA stratiﬁed by sex for boys (L3–4 r = 0.90; L4–5 r =
0.90) and girls (L3–4 r = 0.87; L4–5 r = 0.87). Interrater reliability between independent radiologists (coinvestigators HP
& GC) in a random sample cohort (n = 53, 7%) was excellent,
with intraclass correlation coefﬁcients of 0.97 (95% CI 0.94 to
0.98) at the lumbar level L3–4 and 0.99 (95% CI 0.986 to
0.995) at L4–5. The Bland–Altman plots further support good
agreement for tPMA measurements at L3–4 and L4–5 levels
(Figure S3).
The online tool is available at https://ahrc-apps.shinyapps.
io/sarcopenia/. It uses the results above to display sexspeciﬁc and lumbar level-speciﬁc percentiles of tPMA from
age 1 year to 16 years. A patient’s individual age and tPMA
is overlaid as a point on the chart for visual comparison with
the model and the patient’s age, z-score, and percentile
values are included in text.

Discussion
Drawing on cross-sectional CT imaging from almost 780
healthy children, this study proposes novel sex-speciﬁc references values and percentile curves for total psoas muscle
area at lumbar levels L3–4 and L4–5 for children between

Figure 2 Weight distribution curves stratiﬁed by sex. Weight distribution curves (5th to 95th percentile) for (A) male and (B) female participants from
the Hospital for SickKids (dashed lines) are compared with Center for Disease Control (CDC) growth charts (full lines). Weight curves differ signiﬁcantly
(P < 0.0001) for male and female participants, with this study’s cohort being slightly heavier.
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Figure 3 Total psoas muscle area (tPMA) at lumbar level L3–4 showing 5th to 95th percentiles for (A) male and (B) female participants. tPMA values at
L3–4 increases with patient age.

Figure 4 Total psoas muscle area (tPMA) at lumbar level L4–5 showing 5th to 95th percentiles for (A) male and (B) female participants. tPMA values at
L4–5 increases with patient age.

the ages of 1 and 16 years. Interobserver agreement was excellent at both lumbar levels, highlighting the feasibility of
making these measurements. In addition, we created an online calculator that generates age-speciﬁc and sex-speciﬁc
tPMA percentiles and z-scores, further enhancing the practical application of this measure.
Sarcopenia traditionally denotes the loss of skeletal muscle
mass and function that occurs with the normal aging process.
Sarcopenia can also be a pathologic manifestation of disease
states, including end-stage organ disease, malignancies,6 and
inﬂammatory diseases in children.7,8 The signiﬁcance of
sarcopenia derives from its association with adverse outcomes. For example, in adults with cirrhosis, sarcopenia, as
assessed on CT, has been linked to impaired quality of life,
hepatic decompensation, mortality in patients listed for liver
transplantation (LT), increased length of hospitalization, infection, and higher health care costs.12,22,30–32 Sarcopenia is
closely linked to frailty, a clinical syndrome reﬂecting

increased vulnerability to medical stressors and adverse
health outcomes.33,34 Frailty was ﬁrst described as a clinical
phenotype by Fried and colleagues in older adults.35 Numerous studies have since demonstrated frailty to be a prognostic marker for poorer outcomes in multiple adult
populations.36,37
The concepts of sarcopenia and frailty have been relatively
neglected in the paediatric setting, yet both are likely highly
relevant. Children are not exempt from the unintentional
muscle loss because of nutritional deﬁciencies, physical
deconditioning, and systemic inﬂammation present in chronic
medical illnesses.38 Two paediatric pilot studies reported
smaller tPMA values measured on CT in children with endstage liver disease as well as intestinal and kidney failure19,20
compared with matched healthy controls. Importantly, tPMA
has been observed to have no association with traditional
clinical anthropometric measures, highlighting the potential
role of tPMA (and sarcopenia) as an independent biomarker
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 405–414
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Figure 5 Correlations of weight and total psoas muscle area (tPMA) at lumbar levels L3–4 and L4–5 stratiﬁed by sex. Weight and tPMA highly correlate
for male and female participants at L3–4 and L4–5, respectively. (Pearson’s correlation coefﬁcient r = 0.90 for boys at L3–4 and L4–5 and r = 0.87 for
girls at L3–4 and L4–5). Upper and lower dashed lines represent upper and lower boundaries of the 95% reference range.

of paediatric frailty.19,20 The results of this present study
demonstrated a high correlation of weight and tPMA in
healthy children. In a recent prospective multicentre cohort
study of paediatric chronic liver disease, the assessment of
frailty was adapted for paediatric application; school-age children with end-stage liver disease listed for LT were found to
have signiﬁcantly higher frailty scores than healthy controls,
establishing the relevance of frailty in paediatric as well as
adult populations.39 Because frailty assessments are difﬁcult
in children less than 6 years of age, the availability of an objective biomarker, such as sarcopenia using tPMA measurement, offers the opportunity to be inclusive of the youngest
children who are particularly vulnerable to the sequelae and
morbidities of end-stage organ failure.33,38,40,41
The lack of a consensus deﬁnition for sarcopenia is an important hindrance to the early identiﬁcation of at-risk
patients who would beneﬁt from early nutritional
prehabilitation. In adults and adolescents, CT-based tPMA
values at multiple levels have been published.11,18,42–47 We
elected to evaluate the psoas muscle at two intervertebral

disc levels, L3–4 and L4–547–50 . Although a recent systematic
review highlighted L3 to be a commonly reported level in
adult patients to assess muscle mass on CT,11 anatomical variations may complicate reliable identiﬁcation of borders of
the muscle which often requires multiplanar reformation
and can be time-consuming.50 The psoas muscle becomes
more round and distinct from other paraspinal muscles in
lower lumbar levels (Chavhan, personal communication).
When the vertebral body is used, there is variability in the exact anatomic deﬁnition of the level at which psoas muscle is
measured. In contrast, the intervertebral disc space level is
narrower/thinner and enable a more consistent level determination for measurement of the psoas. Several studies have
reported measurements at L3–L451,52 and L4–L5.48,49,53–55
The feasibility of measuring tPMA at these two levels has
been previously demonstrated in studies assessing
paravertebral muscle area with other muscle groups and
overall strength in adolescents and adults.45,56
Harbaugh et al. recently published paediatric tPMA reference values at the mid-L4 level derived from CT images in
Journal of Cachexia, Sarcopenia and Muscle 2020; 11: 405–414
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children presenting with acute appendicitis or acute traumatic injuries in Michigan.26 Our study provides reference
range curves for tPMA values evaluated at intervertebral
levels from CT scans in children. Additional differences between our study and that by Harbaugh et al. relate to the patient population.26 In Michigan, 76% of the population is
White, followed by 14% Black and 5% Hispanic.57 As supported by the 2016 Canadian census, there is greater ethnic
variation in Toronto (48% White, 13% South Asian, 11% Chinese, 9% Black, 6% Filipino, 3% Hispanic).58 In addition, the
obesity rates amongst children In Canada are lower than
those in USA.59 This is relevant as ethnicity and obesity have
been shown to impact tPMA muscle mass values.60–65 The
tPMA values derived using our Toronto cohort represent a
more diverse population, and we propose to be potentially
more broadly generalizable. We also expect that the availability of reference ranges at two landmarks (rather than one),
coupled with an easy-to-use online calculator, will greatly facilitate the identiﬁcation of at-risk children. Such tools are
needed because current conventional anthropometric measures, such as weight and skinfold thickness, are confounded
by numerous factors, such as ascites or peripheral oedema
and organomegaly, which are common in many chronic diseases. To this point, Suzuki et al. showed that in a paediatric
leukaemia cohort, while some patients lost weight and others
gained, all patients had a decrease in tPMA during induction
treatment.6 tPMA is easily assessed using cross-sectional CT
imaging, which is frequently performed in the work-up of
children with end-stage organ disease, malignancy, and other
chronic conditions.38,66 This is critical as it means additional
scan time is not needed solely for tPMA determination.
Our study has numerous strengths. They include the examination of a large, unbiased, and ethnically diverse paediatric
cohort, with careful exclusion of children with medical conditions that might confound tPMA values. A subset of images
was also read by two experienced radiologists to ensure reproducibility. Furthermore, we examined two levels, rather
than just a single level. The L4–5 level may be the most clinically relevant and useful. This level has been referenced as
the landmark for assessing visceral adipose tissue and thus
one image at this level could be used for measurement of
skeletal muscle (tPMA) and adipose tissue.67,68 The crosssectional psoas muscle shape at L4–5 was also a bit rounder
than at L3–4 (where it was ﬂatter), potentially facilitating
more accurate contour drawing. Interrater reliability was
slightly higher at L4–5 (intraclass correlation coefﬁcient of
0.99). Lastly, an online application was subsequently developed to easily calculate age-speciﬁc and sex-speciﬁc z-scores
and percentiles.
We also acknowledge the limitations of our study. First,
because of low rates of abdominal trauma in children under
1 year, this group of the youngest patients could not be examined. We acknowledge that reference values in this age
group would be particularly helpful especially for infants with

chronic liver disease such as biliary atresia, the most common
indication for paediatric LT.69,70 While CT in children less than
1 year solely for tPMA determination is difﬁcult to justify
given the exposure to ionizing radiation, Tandon and colleagues recently showed excellent agreement between tPMA
assessed using CT and magnetic resonance imaging, the latter
being free of ionizing radiation.71 In the future, magnetic resonance imaging could therefore be considered in these youngest of children to measure tPMA. Second, we were unable
to standardize tPMA by height because of the very limited
height data available in this trauma data set. However, Golse
et al. recently showed that tPMA alone performed identically
to a tPMA:height2 index for predicting 1-year post-LT mortality in adults with area under the curve of 0.753.16 Finally, our
population was on average 3–4 kg heavier than standard CDC
curves.28 These CDC curves were derived in the early 2000s,
whereas our population spanned 2005–2015, such that the
differences are likely to reﬂect secular trends in body weight
in North America.72
In conclusion, we have deﬁned novel paediatric reference
curves for total psoas muscle area as a marker of sarcopenia
in children, along with an online calculator to facilitate ease of
use. These tools will greatly facilitate the identiﬁcation of children at risk for sarcopenia to enable early implementation of
targeted therapies to avoid associated comorbidity and optimize outcomes. In addition, these tools have important research applications and will help elucidate the relationship
between sarcopenia and frailty and, ultimately, the prognostic signiﬁcance of these parameters.
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L4-5 (ICC = 0.99).
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